RxDoctor Payments Data

Jonathan Weiss, MD

Psychiatry · North Andover, MANPI 1528119385

Payments from drug & device makers

$851in general payments, 2019–2025

Across 49 payments — averaging $17.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$211
  • Johnson & Johnson$180
  • Vanda Pharmaceuticals Inc.$165
  • Shire North American Group Inc$127
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$120
  • AbbVie$20
  • plus $28 from 2 others

What the payments were for

  • Food & beverage$68581%
  • Education$16519%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$851 in reported general payments places this provider in the 80th percentile of 1,431 psychiatry providers in Massachusetts.

See all psychiatry providers in Massachusetts

Medicare billing

Part B allowed, 2024
$77,485
Medicare patients
119
Services billed
943

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate13$29,326
RexultiBrexpiprazole18$28,201
TrintellixVortioxetine Hydrobromide29$22,289
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine519$18,063
VyvanseLisdexamfetamine Dimesylate29$11,275
Aripiprazole223$9,641
Adderall XrDextroamphetamine/Amphetamine22$8,225
Bupropion XlBupropion Hcl320$6,749
Vilazodone Hcl69$6,153
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine93$5,823
Lisdexamfetamine Dimesylate26$5,093
Alprazolam404$3,836
Clonazepam385$3,693
Venlafaxine Hcl ErVenlafaxine Hcl150$2,873
Quetiapine Fumarate134$2,851

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$180$29,32613 claims
Otsuka America Pharmaceutical, Inc.Rexulti$211$28,20118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,431 psychiatry providers in Massachusetts.

Other psychiatry in North Andover

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →